Peginterferon Alfa-2a
Interferons
Sold as PEGASYS
- Drug class
- Interferons
- Availability
- See label
- Routes
- Subcutaneous
- Markets covered
- 3
- Products on record
- 6
Overview
Peginterferon Alfa-2a is an active pharmaceutical ingredient in the Interferons group (L03AB). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 4 | January 16, 2026 |
| CA Canada | Health Canada | 1 | November 24, 2025 |
| EU European Union | EMA | 1 | November 5, 2025 |
GBUnited Kingdom· MHRA
4 products
Uses
1). Paediatric patients 3 years of age and older Pegasys is indicated for the treatment of HBeAg-positive CHB in non- cirrhotic children and adolescents 3 years of age and older with evidence of viral replication and persistently elevated serum ALT levels.
1. 1). 1. Paediatric patients 5 years of age and older Pegasys in combination with ribavirin is indicated for the treatment of CHC in treatment-naïve children and adolescents 5 years of age and older who are positive for serum HCV-RNA.
When deciding to initiate treatment in childhood, it is important to consider growth inhibition induced by combination therapy. The reversibility of growth inhibition is uncertain. 4).
How to take
CACanada· Health Canada
1 product
Uses
5 mL PART I: HEALTH PROFESSIONAL INFORMATION SUMMARY PRODUCT INFORMATION Information as set forth in this label only applies to PEGASYS. 0 mL Benzyl alcohol For a complete listing see Dosage Forms, Composition and Packaging section.
5 mL Benzyl alcohol For a complete listing see Dosage Forms, Composition and Packaging section.
DESCRIPTION PEGASYS:
Peginterferon alfa-2a is a covalent conjugate of recombinant alfa-2a interferon (approximate molecular weight [MW] 20 kD) with a single branched bis-monomethoxy polyethylene glycol (PEG) chain (approximate MW 40 kD). Interferon alfa-2a is produced biosynthetically using recombinant DNA technology, and is the product of a cloned human leukocyte interferon gene inserted into and expressed in E.
coli. INDICATIONS AND CLINICAL USE Chronic Hepatitis C (CHC) PEGASYS (peginterferon alfa-2a) is indicated for the treatment of Chronic Hepatitis C in: • Adult patients without cirrhosis • Adult patients with compensated cirrhosis, including HCV/HIV co-infection patients with stable HIV disease with or without antiretroviral therapy.
EUEuropean Union· EMA
1 product
Uses
1). Paediatric patients 3 years of age and older Pegasys is indicated for the treatment of HBeAg-positive CHB in non-cirrhotic children and adolescents 3 years of age and older with evidence of viral replication and persistently elevated serum ALT levels.
1. 1). 1. Paediatric patients 5 years of age and older Pegasys in combination with ribavirin is indicated for the treatment of CHC in treatment-naïve children and adolescents 5 years of age and older who are positive for serum HCV-RNA.
When deciding to initiate treatment in childhood, it is important to consider growth inhibition induced by combination therapy. The reversibility of growth inhibition is uncertain. 4).
How to take
Drug interactions
Known interactions involving Peginterferon Alfa-2a. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PLGB545990006 · revised January 16, 2026
- [2]Health Canada (DPD) · 02248077 · revised November 24, 2025
- [3]European Medicines Agency · EMEA/H/C/000395 · revised November 5, 2025
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.